Kyntra Bio (LTS:0IL8) ROE % Adjusted to Book Value: 0.00% (As of Mar. 2026)


LTS:0IL8 Kyntra Bio Inc LTS:0IL8
50 GF Score
Price $7.45
GF Value $5.70
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Kyntra Bio ROE % Adjusted to Book Value?

Kyntra Bio LTS:0IL8 -1.94% 50 ROE % Adjusted to Book Value is 0.00% as of Mar. 2026. GuruFocus rates LTS:0IL8 with a GF Score™ of 50/100 and a GF Value™ of $5.70 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Kyntra Bio's ROE % for the quarter that ended in Mar. 2026 was 0.00%. Kyntra Bio's PB Ratio for the quarter that ended in Mar. 2026 was N/A. Kyntra Bio's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was N/A.

Kyntra Bio ROE % Adjusted to Book Value Related Terms

Kyntra Bio ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Kyntra Bio's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kyntra Bio ROE % Adjusted to Book Value Chart

Kyntra Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -14.68 0.00 0.00 0.00 Negative Equity

Kyntra Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Negative Equity 0.00 Negative Equity 0.00 0.00

LTS:0IL8 vs TVGN, PSTV, GRDX: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Kyntra Bio's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kyntra Bio ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kyntra Bio's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Kyntra Bio's ROE % Adjusted to Book Value falls into.


LTS:0IL8
50GF Score
Kyntra Bio Inc LTS:0IL8
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kyntra Bio ROE % Adjusted to Book Value Calculation

Kyntra Bio's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=Negative Equity / N/A
=Negative Equity

Kyntra Bio's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 0.00% mean?
Kyntra Bio (LTS:0IL8) has a ROE % Adjusted to Book Value of 0.00% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Kyntra Bio and its competitors.
Is Kyntra Bio's ROE % Adjusted to Book Value too high?
Kyntra Bio's current ROE % Adjusted to Book Value is 0.00%. Overall, Kyntra Bio has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kyntra Bio's ROE % Adjusted to Book Value compare to TVGN and PSTV?
Kyntra Bio's ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Kyntra Bio and its competitors. Kyntra Bio's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyntra Bio stock overvalued right now?
Based on GuruFocus' analysis, Kyntra Bio (LTS:0IL8) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.70, compared to a current price of $7.45 — trading 30.8% above its estimated fair value. The current ROE % Adjusted to Book Value is 0.00%. Kyntra Bio's overall GF Score™ is 50/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Kyntra Bio (LTS:0IL8), the current ROE % Adjusted to Book Value is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kyntra Bio (LTS:0IL8) Overvalued in 2026?

Based on GuruFocus' analysis, Kyntra Bio stock appears to be overvalued. The current stock price of $7.45 is trading 30.8% above its estimated GF Value™ of $5.70. GuruFocus considers Kyntra Bio to be Significantly Overvalued.

Key valuation signals for LTS:0IL8:

  • ROE % Adjusted to Book Value: 0.00%
  • GF Value™: $5.70 vs. price of $7.45 (30.8% above fair value)
  • GF Score™: 50/100 with 8 warning signs

No single metric tells the full story. See the LTS:0IL8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kyntra Bio Business Description

Address 350 Bay Street, Suite 100, No. 6009, San Francisco, CA, USA, 94133
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
50GF Score

Get the complete analysis for LTS:0IL8

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.45
Price
$5.70
GF Value